Login to Your Account



Mismatch catch pays off in Keytruda vs. colorectal

By Randy Osborne
Staff Writer

Friday, May 29, 2015
CHICAGO – Genomics may matter more than histology in predicting the response rate of patients treated with the PD-1 inhibitor Keytruda (pembrolizumab, Merck & Co. Inc.), as a phase II study has turned up the first genomic marker – mismatch repair deficiency – that foretells success, results showed at the ASCO annual meeting.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription